Biogen Looks to Extend its MS Leadership Through Licensing
By Jasmine Kalsi
Pharma Deals Review: Vol 2017 Issue 12 (Table of Contents)
Published: 19 Dec-2017
DOI: 10.3833/pdr.v2017.i12.2290 ISSN: 1756-7874
Section: Licensing
Fulltext:
Abstract
In order to mitigate the threat to its multiple sclerosis (MS) franchise, Biogen has in-licensed Alkermes’ ALKS-8700; a drug which was developed to match the efficacy and have an improved safety profile compared with Biogen’s Tecfidera® (dimethyl fumarate)...
This page is available to subscribers only.
Not a subscriber? Join here
Already Registered? Please login using the top left purple box.
Copyright: © IQVIA 2018
RSS